| Literature DB >> 33532575 |
Thissa N Siriwardena1, Bee-Ha Gan1, Thilo Köhler2, Christian van Delden2, Sacha Javor1, Jean-Louis Reymond1.
Abstract
Solid-phase peptide synthesis (SPPS) is usually performed with optically pure building blocks to prepare peptides as single enantiomers. Herein we report that SPPS using racemic amino acids provides stereorandomized (sr) peptides, containing up to billions of different stereoisomers, as well-defined single HPLC peaks, single mass products with high yield, which can be used to investigate peptide bioactivity. To exemplify our method, we show that stereorandomization abolishes the membrane-disruptive effect of α-helical amphiphilic antimicrobial peptides but preserves their antibiofilm effect, implying different mechanisms involving folded versus disordered conformations. For antimicrobial peptide dendrimers by contrast, stereorandomization preserves antibacterial, membrane-disruptive, and antibiofilm effects but reduces hemolysis and cytotoxicity, thereby increasing their therapeutic index. Finally, we identify partially stereorandomized analogues of the last resort cyclic peptide antibiotic polymyxin B with preserved antibacterial activity but lacking membrane-disruptive and lipopolysaccharide-neutralizing activity, pointing to the existence of additional targets.Entities:
Year: 2021 PMID: 33532575 PMCID: PMC7845017 DOI: 10.1021/acscentsci.0c01135
Source DB: PubMed Journal: ACS Cent Sci ISSN: 2374-7943 Impact factor: 14.553
Figure 1Synthesis of stereorandomized peptides and peptide dendrimers. (a) Stereorandomized SPPS of AMP sr-SB1 and AMPD sr-G3KL. SPPS conditions: (a) 20% v/v piperidine in DMF, 2 min, 25 °C and 5 min, 50 °C; (b) FmocAAOH (5 equiv), Oxyma (7.5 equiv), DIC (10 equiv),10 min, 50 °C; (c) TFA/TIS/H2O (94:5:1), 4 h at room temperature. (b) CD spectra of l-, d- and sr-SB1 and (c) CD spectra of l-, d-, and sr-G3KL, at 200 μg/mL TFA salt of the compound in 6 mM aq. phosphate buffer pH 7.4 with the 20% of TFE added. (d) Serum stability assay. Conditions: 400 μM compound in aq. 0.1 M Tris buffer pH 7.5 containing 25% v/v human serum.
Synthesis and Activity of Homochiral (l- or d-), Stereorandomized (sr-) and Racemic (-rac) Antimicrobial Peptides, Peptide Dendrimers, and Polymyxin B
| Cpd. | SPPS yield | MS analysis | analytical HPLC | EYPG vesicle leakage | EYPC vesicle leakage | hemolysis on hRBC, MHC | PAO1 biofilm MBIC | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| mg (%) | calc./obs. | MIC (μg/mL) | (%) | (%) | (μg/mL) | (μg/mL) | |||||
| Linear Peptides | |||||||||||
| L- | 56 (30) | 1543.07/1543.08 | 1.53 | 2 | 2 | 0.5 | 32 | 60 | 52 | >2000 | 16 |
| D- | 74 (26) | 1543.07/1543.07 | 1.55 | 1 | 2 | 0.5 | 32 | 70 | 45 | >2000 | 8 |
| - | - | - | 2 | 2 | 1 | 16 | 91 | 51 | >2000 | 16 | |
| 62 (22) | 1543.07/1543.08 | 1.53 | >64 | >64 | 32 | >64 | 12 | 1 | >2000 | 16 | |
| 48 (17) | 1543.07/1543.07 | 1.54 | >64 | >64 | 16 | >64 | 20 | 9 | >2000 | 16 | |
| 57(20) | 1543.07/1543.07 | 1.54 | >64 | >64 | 16 | >64 | 27 | 6 | >2000 | 16 | |
| L- | 22 (9) | 1549.98/1549.98 | 1.53 | 32 | 16 | 32 | >64 | 32 | 1 | >2000 | >32 |
| D- | 19 (7) | 1549.98/1549.98 | 1.50 | 4–2 | 8 | 4–2 | 2 | 36 | 2 | 1000 | 8 |
| 13 (8) | 1549.98/1549.98 | 1.52 | >64 | >64 | 16 | >64 | 8 | 1 | >2000 | 32 | |
| L- | 28 (10) | 1905.05/1905.04 | 1.80 | >64 | 16 | 32 | 32 | 18 | 18 | 125 | >32 |
| D- | 22 (8) | 1905.05/1905.05 | 1.82 | >64 | 16 | 16 | 32 | 35 | 18 | 125 | >32 |
| 18 (7) | 1905.05/1905.05 | 1.87 | >64 | 8 | 16 | 16 | 18 | 37 | 125 | >32 | |
| Peptide Dendrimers | |||||||||||
| L- | 124 (23) | 4531.38/4531.43 | 1.47 | 2 | 4 | 1 | >64 | 42 | 6 | 1000 | 16 |
| D- | 142 (17) | 4531.38/4531.37 | 1.46 | 4 | 8 | 1 | 32 | 51 | 8 | 1000 | 16 |
| - | - | - | 4 | 8 | 2 | >64 | 77 | 1 | 1000 | 16 | |
| 138 (24) | 4531.38/4531.43 | 1.53 | 8 | >64 | 8 | >64 | 38 | 1 | 1000 | 16 | |
| 94 (11) | 4531.38/4531.43 | 1.54 | 4 | >64 | 8 | >64 | 58 | 1 | 1000 | 16 | |
| 86 (10) | 4531.38/4531.44 | 1.52 | 8 | >64 | 4 | >64 | 66 | 1 | 1000 | 16 | |
| L- | 121 (42) | 2395.61/2395.61 | 1.64 | 2 | 2 | 4 | >64 | 64 | 1 | 1000 | 8 |
| D- | 156 (14) | 2395.61/2395.60 | 1.63 | 4 | 8 | 4 | >64 | 65 | 5 | 500 | 8 |
| - | - | - | 4 | 4 | 2 | >64 | 76 | 3 | 500 | 16 | |
| 8 (4) | 2395.61/2395.60 | 1.64 | 4 | 8 | 4 | >64 | 61 | 3 | 1000 | 16 | |
| L- | 26 (7) | 4614.44/4614.47 | 1.55 | 4 | 4 | 4 | 16 | 50 | 31 | 62.5 | 8 |
| D- | 57 (7) | 4614.44/4614.45 | 1.59 | 4 | 2 | 8 | 16 | 45 | 28 | 125 | 8 |
| - | - | - | 4 | 4 | 8 | 16 | 46 | 37 | 31.25 | 8 | |
| 3854 (23) | 4614.44/4614.44 | 1.59 | 2 | 8 | 4 | 32 | 40 | 1 | >2000 | 8 | |
| 34 (6) | 4614.44/4614.45 | 1.61 | 4 | 4 | 4 | 32 | 58 | 8 | 62.5 | >16 | |
| 26 (5) | 4614.44/4614.43 | 1.57 | 4 | 16 | 4 | >64 | 67 | 2 | >2000 | 16 | |
| Cyclic Peptides | |||||||||||
| polymyxin B ( 10 residues, 1024 possible diastereomers) | |||||||||||
| - | - | - | 0.25 | 0.25 | 0.25 | 0.25 | 53 | 2 | >2000 | 8 | |
| 26 (3) | 1188.73/1188.74 | 1.58 | 0.25 | 0.25 | 0.25 | 0.5 | 39 | 1 | >2000 | 8 | |
| 148 (14) | 1188.73/1188.74 | 1.55 | 32 | 64 | 2 | >64 | 5 | 6 | >2000 | >16 | |
| 24 (5) | 1188.73/1188.74 | 1.56 | 4 | 4 | 1 | >64 | 1 | 1 | >2000 | 16 | |
| 18 (3) | 1188.73/1188.74 | 1.58 | 2 | 2 | 0.25 | 2 | 1 | 1 | >2000 | 16 | |
One-letter codes for amino acids, K = branching lysine l- and d- sequences are with only l- or only d-amino acids, sr-sequences have all positions individually racemized corresponding to the indicated number of diastereomers, and rac-sequences are a 1:1 mixture of all l- and all d-sequences, in sr-T25a and sr-T25b only the residues underlined are racemic, see Figures and 4 for structural formulas of AMPDs and PMB.
Yields given for RP-HPLC purified product.
High-resolution electrospray ionization mass spectrometry (positive mode), the calculated monoisotopic mass, and the observed mass in the reconstructed spectrum are given.
Retention time in analytical RP-HPLC (A/D = 100/0 to 0/100 in 2.2 min, λ = 214 nm).
Minimum inhibitory concentration (MIC, μg/mL) was determined on P. aeruginosa PAO1, A. baumannii ATCC 19606, E. coli W3110 and K. pneumoniae NCTC418 in Müller-Hinton medium, after incubation for 16–20 h at 37 °C.
Lipid vesicles made of egg yolk phosphatidyl glycerol (EYPG) or egg yolk phosphatidyl choline (EYPC) were suspended in buffer (10 mM TRIS, 107 mM NaCl, pH 7.4). After 50 s, the indicated compound was added to reach the indicated concentration. After 300 s, 1.2% Triton X-100 was added for full fluorescein release. The percentage leakage observed with 10 μg/mL compound at 250 s is given. Full curves are given in Figures S8–S14.
Minimum hemolytic concentration (MHC) measured on human red blood cells in 10 mM phosphate, 150 mM NaCl, pH 7.4, 25 °C, 4.
Minimum biofilm inhibitory concentration (MBIC, μg/mL) was measured in 0.25% (w/v) nutrient broth no. 2, Oxoid on P. aeruginosa PAO1. All experiments were done in at least two independent duplicates, see the Supporting Information for details.
Figure 4Stereorandomization of polymyxin B2. (a) Solid phase total synthesis of polymyxin B2. Conditions: a) linear chain synthesis by SPPS; b) on-resin cyclization: (i) Pd(Ph3)4 (0.25 equiv), PhSiH3 (25 equiv), in dry DCM, (ii) Fmoc deprotection with 20% v/v piperidine in DMF, (iii) Oxyma (7.5 equiv), DIC (10 equiv), 25 °C,12 h ; c) TFA cleavage with TFA/TIS/H2O (94:5:1), 4 h, 25 °C, then HPLC purification. (b) Membrane-disruptive properties of commercial polymyxin and synthetic polymyxin B analogues (10 mM TRIS, 107 mM NaCl, pH 7.4). After 50 s the indicated compound was added to reach the indicated concentration. After 300 s 1.2% Triton X-100 was added for full fluorescein release. (c) Determination of TNF-α expression level in Raw264.7 murine macrophages by ELISA immunoassay. Polymyxin derivatives were coincubated with or without 0.1 μg/mL of E. coli LPS containing 1 or 10% FBS for 4 h at 37 °C and 5% CO2. (d) TEM images of E. coli cells treated for 60 min at 20 × MIC with polymyxin B analogues. see the Supporting Information for details.
Figure 2Vesicle leakage assays with homochiral and stereorandomized SB1 (a) and G3KL (b). Lipid vesicles made of egg yolk phosphatidyl glycerol (EYPG) or egg yolk phosphatidyl choline (EYPC) were suspended in buffer (10 mM TRIS, 107 mM NaCl, pH 7.4). After 50 s, the indicated compound was added to reach the indicated concentration. After 300 s, 1.2% Triton X-100 was added for full fluorescein release. The bar plots report relative fluorescence signal intensity measured after 250 s at 10 μg/mL.
Figure 3Full and partial stereorandomization of AMPD T25. (a) Cytotoxicity of G3KL, polymyxin B, and T25 analogues in HepG2 cells in DMEM containing 10% FBS. (b) Vesicle leakage assays. (c) TEM images of P. aeruginosa cells treated for 60 min at 10× MIC with sr-T25 (40 μg/mL). (d) CD spectra of T25 analogues (TFA salt 200 μg/mL) in aq. 6 mM phosphate pH 7.4 upon addition of 20% TFE. (e) Molecular dynamics simulation of dendrimer l-T25. Stick model of MD structures color-coded by dendrimer generation (red = G0, orange = G1, blue = G2, black = G3) highlighting the α-helical fold. (f) Cut-out view of (e) showing the G1-G0 α-helical core of l-T25 (brown = leucine, blue = lysine, gray = branching lysine).